Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares OutstandingShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Arrowhead Pharmaceuticals (ARWR) Shares Issued: 2010-2025

Historic Shares Issued for Arrowhead Pharmaceuticals (ARWR) over the last 6 years, with Mar 2025 value amounting to $216.4 million.

  • Arrowhead Pharmaceuticals' Shares Issued fell 49.56% to $216.4 million in Q1 2025 from the same period last year, while for Mar 2025 it was $670.7 million, marking a year-over-year increase of 55.52%. This contributed to the annual value of $241.4 million for FY2025, which is 43.77% down from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Shares Issued of $216.4 million as of Q1 2025, which was up 765.55% from $25.0 million recorded in Q4 2024.
  • Arrowhead Pharmaceuticals' 5-year Shares Issued high stood at $429.0 million for Q1 2024, and its period low was $267,000 during Q4 2023.
  • Its 3-year average for Shares Issued is $96.2 million, with a median of $1.1 million in 2023.
  • Its Shares Issued has fluctuated over the past 5 years, first skyrocketed by 131,550.00% in 2021, then tumbled by 97.98% in 2023.
  • Arrowhead Pharmaceuticals' Shares Issued (Quarterly) stood at $1.9 million in 2021, then tumbled by 69.44% to $576,000 in 2022, then slumped by 53.65% to $267,000 in 2023, then skyrocketed by 9,263.30% to $25.0 million in 2024, then crashed by 49.56% to $216.4 million in 2025.
  • Its Shares Issued was $216.4 million in Q1 2025, compared to $25.0 million in Q4 2024 and $429.0 million in Q1 2024.